Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Snigzole D
- Development stage
- Unknown
- Lead developer
- Snig Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Snigzole D is a fixed-dose combination drug product developed and marketed by SNIG Pharma. It is formulated as a capsule containing pantoprazole (40 mg) and domperidone (30 mg). Pantoprazole is a small molecule proton pump inhibitor that irreversibly binds to the H+/K+-ATPase enzyme system (the proton pump) of the gastric parietal cell, effectively suppressing the final step of gastric acid production. Domperidone is a dopamine D2 receptor antagonist that acts as a prokinetic agent, increasing lower esophageal sphincter pressure and enhancing gastric emptying. This combination is primarily used for the management of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related gastrointestinal disorders where both acid suppression and improved motility are clinically indicated. The product is approved and marketed in India.
- Brand names
- Snigzole D
- Other names
- domperidone + pantoprazole
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on Snigzole D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Snigzole D.